Remarks: Saracatinib is highly selective for Src and Abl kinases against a large range of tyrosine and serine-threonine kinases (VEGFR2, FGFR, c-Kit, Aur-3 etc. >5 µM). Saracatinib exerts its activity through ATP competitive and reversible inhibition of the target enzyme. [1]Saracatinib potently inhibited the in vitro proliferation of Src3T3 mouse fibroblasts and demonstrated variable antiproliferative activity in a range of human cancer cell lines containing endogenous Src. Sub micromolar growth inhibition of five of the human cancer cell lines tested with Saracatinib(tumor types: colon, prostate, lung, and leukemia) was observed with IC50 values of 0.2¨C0.7 µM. In 3-day MTS cell proliferation assays, AZD0530 inhibited in vitro proliferation of the Bcr¨CAbl-driven human leukemia cell line K562 with an IC50 of 0.22 µM.In a head-to-head assay measuring EGFR phosphorylation in KB cells, Saracatinib exhibited an IC50 of 1.25 mM compared with 11 nM for gefitinib.
None of the products will be supplied to countries in which this could be in conflict with the existing patents. However the final responsibility lies with the Buyer.